This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Christine Lovly, MD, PhD, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT00897650
First received: May 9, 2009
Last updated: July 18, 2017
Last verified: July 2017
May 9, 2009
July 18, 2017
December 2005
July 2016   (Final data collection date for primary outcome measure)
DNA, RNA, and Protein expression patterns and mutational analysis [ Time Frame: After lung tumor tissue and blood collection. ]
DNA, RNA, and Protein expression patterns and mutation status in lung tumor tissue that are capable of predicting tumor response to therapy
  • Protein and/or RNA expression patterns
  • Characterization of genes and proteins predictive of response
Complete list of historical versions of study NCT00897650 on ClinicalTrials.gov Archive Site
Characterization of genes and proteins predictive of response to therapy [ Time Frame: After lung tumor tissue and blood collection ]
Identify genes and proteins predictive of response to therapy and that can be used to identify novel mechanisms underlying lung cancer behavior
Not Provided
Not Provided
Not Provided
 
Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy

RATIONALE: Studying samples of tumor tissue and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in genetic material (DNA and RNA) and may also identify protein expression patterns related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study evaluates changes in DNA, RNA, and proteins with the goal of predicting response to treatment in patients with lung cancer.

OBJECTIVES:

  • To determine protein and/or RNA expression patterns capable of predicting tumor response to therapy in tumor tissue samples from patients with lung cancer or suspected of having lung cancer.
  • To characterize the genes and proteins found to be predictive of response in order to help elucidate the molecular biology underlying cancer chemosensitivity.
  • To evaluate DNA mutations found within the lung cancer sample which may be predictive of response or resistance to certain therapeutic agents.

OUTLINE: Patients undergo collection of tumor tissue by percutaneous fine needle aspiration, core biopsy, thoracentesis, or during any medically indicated procedure involving removal of lung cancer tissue. Tissue samples are analyzed by a variety of techniques, including DNA sequencing, RNA sequencing and expression levels, protein assessment [by immunohistochemistry, western blot, Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-MS]). The goal of these studies is to identify of gene mutations, gene expression levels, and proteins predictive of treatment response. Blood samples are also collected to obtain normal DNA for analysis.

After completion of study, patients will be followed until their death.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Lung tumor tissue and blood samples will be collected.
Non-Probability Sample
People who have or may have lung cancer.
Lung Cancer
  • Genetic: DNA/RNA sequencing and expression levels
    Lung tumor tissue will be collected.
  • Genetic: Protein expression analysis
    Lung tumor tissue will be collected.
    Other Names:
    • Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI)
    • Immunohistochemistry
    • Western blot
    • RPPA
  • Procedure: Lung tumor biopsy
    Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
  • Procedure: Blood sample
    Patients will be asked for a venous blood sample
Lung cancer
Patients with a diagnosis of invasive lung cancer.
Interventions:
  • Genetic: DNA/RNA sequencing and expression levels
  • Genetic: Protein expression analysis
  • Procedure: Lung tumor biopsy
  • Procedure: Blood sample
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
204
July 2017
July 2016   (Final data collection date for primary outcome measure)

Inclusion criteria

  • Diagnosis of suspected lung cancer or lung cancer

Exclusion criteria

  • Inability to undergo therapy
Sexes Eligible for Study: All
up to 120 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00897650
VICC THO 0547
P30CA068485 ( U.S. NIH Grant/Contract )
VU-VICC-THO-0547 ( Other Identifier: VICC )
P50CA090949 ( U.S. NIH Grant/Contract )
No
Not Provided
Not Provided
Christine Lovly, MD, PhD, Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Study Chair: Christine Lovly, MD, PhD Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP